Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 4/20 | 0.42 |
| ▸ | ACHE | P22303 | 5/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | BRD2 | P25440 | 1/20 | 0.36 |
| ▸ | LSS | P48449 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6337188 | 1.00 | ROCK2 (0.43) | ROCK2CYP3A4RETACHECYP2C19 | |
| SCHEMBL6331490 | 0.92 | ACHE (0.44) | RETACHEBCHEEGFRMEN1 | |
| SCHEMBL6331498 | 0.92 | ACHE (0.44) | RETACHEBCHEEGFRMEN1 | |
| SCHEMBL6336778 | 0.91 | ACHE (0.45) | RETACHEBCHE | |
| SCHEMBL6336786 | 0.91 | ACHE (0.45) | RETACHEBCHE | |
| SCHEMBL6336801 | 0.90 | ACHE (0.52) | RETACHEBCHE | |
| SCHEMBL6336549 | 0.90 | RET (0.40) | ROCK2CYP3A4RETACHEBCHE | |
| SCHEMBL6339151 | 0.90 | ACHE (0.40) | ROCK2CYP3A4RETACHEBCHE | |
| SCHEMBL6336805 | 0.90 | ACHE (0.52) | RETACHEBCHE | |
| SCHEMBL6336552 | 0.90 | RET (0.40) | ROCK2CYP3A4RETACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-13 | — | — | US | disclosed |
| US-6794395-B1 | Substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | CCNE1, CDK1, CCNI | ROCK2 1396/4885CYP3A4 533/4885RET 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.